Soria

Soria is a preclinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative and neurological disorders. The company utilizes a proprietary nanoparticle-based delivery platform designed to enhance the transport of small molecules across the blood-brain barrier and target specific cellular pathways in the central nervous system. Soria's lead programs focus on modulating glutamate transporters, specifically EAAT2, to address excitotoxicity in conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. By combining innovative drug delivery technology with deep expertise in neurobiology, Soria aims to overcome the historical challenges of treating brain-related pathologies.